Skip to main content

Menu

Select a tool from the sidebar

Create your free account now!

Sign in to customize and use tools on the sidebar.

Sign InCreate free account
AstraZeneca PLC logo
AZN.L
AstraZeneca PLC
13:27:20
13316 £
0.0000 (%0.00)
Previous Close: 13154
Day Low₺13222
Day High₺13396
Bid
Ask
Overview
Technicals
Financial Statements
Comments
Archive

AZN.L: AstraZeneca PLC Financials

AstraZeneca PLC Income Statement

Total revenue
Net income
Gross margin TTM
81.9%
Operating margin TTM
23.4%
Net profit margin TTM
17.41%
Return on investment TTM
21.01%
Period end31/12/202531/12/202431/12/202331/12/2022
Total revenue58,739,000,00052,943,888,00046,583,069,00044,253,418,000
Operating income13,743,000,00012,521,950,0009,569,607,0005,048,867,000
Net income10,225,000,0006,888,100,0006,055,362,0003,280,766,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Total revenue58,739,000,00052,943,888,00046,583,069,00044,253,418,000
Cost of revenue10,633,000,00013,245,519,00012,135,128,00016,213,249,000
Gross profit48,106,000,00039,698,370,00034,447,941,00028,040,170,000
Research and development expenses14,232,000,00011,962,873,00010,519,348,0009,617,792,000
General and administrative expenses19,933,000,000000
Selling and marketing expenses579,000,000000
Selling, general and administrative expenses20,512,000,00015,213,547,00014,358,986,00013,373,511,000
Other expenses-381,000,000000
Operating expenses34,363,000,00027,176,420,00024,878,334,00022,991,303,000
Cost and expenses44,996,000,00040,421,939,00037,013,462,00039,204,551,000
Net interest income-1,334,000,000-1,030,033,000-855,174,000-809,216,000
Interest income360,000,000331,921,000295,904,00077,828,000
Interest expense1,694,000,0001,361,954,0001,151,078,000887,044,000
Depreciation and amortization5,733,000,0004,959,236,0005,017,154,0005,242,440,000
EBITDA19,829,000,00014,858,127,00013,195,706,0008,629,970,000
EBIT14,096,000,0009,898,891,0008,178,551,0003,387,530,000
Non-operating income (excl. interest)-353,000,0002,623,059,0001,391,055,0001,661,337,000
Operating income13,743,000,00012,521,950,0009,569,607,0005,048,867,000
Total other income/expenses (net)-1,341,000,000-4,012,429,000-2,554,336,000-2,553,370,000
Income before tax12,402,000,0008,509,521,0007,015,271,0002,495,497,000
Income tax expense2,169,000,0001,615,546,000953,808,000-790,257,000
Net income from continuing operations10,233,000,0006,893,975,0006,061,463,0003,285,755,000
Net income from discontinued operations0000
Other adjustments to net income0000
Net income10,225,000,0006,888,100,0006,055,362,0003,280,766,000
Net income deductions0000
Bottom line net income10,225,000,0006,888,100,0006,055,362,0003,280,766,000
EPS7442
Diluted EPS7442
Weighted average shares outstanding1,550,000,0001,550,000,0001,562,000,0001,548,000,000
Weighted average diluted shares outstanding1,562,000,0001,563,000,0001,562,000,0001,560,000,000

AstraZeneca PLC Balance Sheet

Total assets
Total liabilities & equity
Liquidity ratio MRQ
—
Current ratio MRQ
—
Long-term debt / assets MRQ
24,715,000,000%
Total debt / assets MRQ
—
Period end31/12/202531/12/202431/12/202331/12/2022
Total assets114,074,000,000104,035,000,000101,119,000,00096,483,000,000
Total liabilities65,355,000,00063,164,000,00061,953,000,00059,425,000,000
Total equity48,667,000,00040,786,000,00039,143,000,00037,037,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Cash and cash equivalents5,711,000,0005,482,435,0005,790,531,0006,166,000,000
Short-term investments30,000,000165,832,000120,967,00077,000,000
Cash and short-term investments5,741,000,0005,648,267,0005,911,497,0006,243,000,000
Net receivables16,340,951,00013,080,722,00011,833,901,0009,192,000,000
Accounts receivable15,177,000,0008,293,581,0008,335,786,0007,212,000,000
Other receivables1,158,422,0004,787,141,0003,498,115,0001,980,000,000
Inventory6,557,000,0005,282,638,0005,378,054,0004,699,000,000
Prepaid expenses01,735,239,0001,603,303,0001,329,000,000
Other current assets84,049,00053,944,000115,018,0001,130,000,000
Total current assets28,723,000,00025,800,810,00024,841,773,00022,593,000,000
Property, plant and equipment (net)14,703,000,00011,647,000,00010,502,000,0009,449,000,000
Goodwill21,242,000,00021,025,000,00019,878,177,00019,820,000,000
Intangible assets37,846,000,00037,177,000,00038,089,000,00039,307,000,000
Goodwill and intangible assets59,088,000,00058,202,000,00058,137,000,00059,127,000,000
Long-term investments5,743,091,0002,554,407,0002,322,161,0001,142,000,000
Tax assets5,819,000,0005,347,000,0004,718,000,0003,263,000,000
Other non-current assets-2,091,000457,593,000385,839,000909,000,000
Total non-current assets85,351,000,00078,208,000,00076,065,000,00073,890,000,000
Other assets0000
Total assets114,074,000,000104,035,000,000101,119,000,00096,483,000,000
Total payables26,364,000,0008,058,000,0007,623,000,0005,841,000,000
Accounts payable25,280,000,0003,640,000,0003,267,000,0002,550,000,000
Other payables1,084,000,0004,418,000,0004,356,000,0003,291,000,000
Accrued expenses0000
Short-term debt3,104,000,0002,156,000,0004,914,000,0005,225,000,000
Capital lease obligations (current)382,000,000339,000,000271,000,000228,000,000
Tax payables1,084,000,0001,406,000,0002,076,000,000896,000,000
Deferred revenue0000
Other current liabilities767,000,00017,313,000,00017,734,000,00014,999,000,000
Total current liabilities30,617,000,00027,866,000,00030,542,000,00026,293,000,000
Long-term debt24,715,000,00026,506,000,00022,365,000,00022,965,000,000
Capital lease obligations (non-current)1,421,000,0001,113,000,000857,000,000725,000,000
Deferred revenue (non-current)007,000,00014,000,000
Deferred tax liabilities (non-current)3,500,000,0003,305,000,0002,844,000,0002,944,000,000
Other non-current liabilities5,102,000,0004,374,000,0005,338,000,0006,484,000,000
Total non-current liabilities34,738,000,00035,298,000,00031,411,000,00033,132,000,000
Other liabilities0000
Capital lease obligations1,803,000,0001,452,000,0001,128,000,000953,000,000
Total liabilities65,355,000,00063,164,000,00061,953,000,00059,425,000,000
Treasury stock0000
Preferred stock0000
Common stock388,000,000388,000,000388,000,000387,000,000
Retained earnings10,972,000,0003,160,000,0001,502,000,000-574,000,000
Additional paid-in capital35,266,000,00035,379,000,00035,341,000,00035,308,000,000
Accumulated other comprehensive income/loss0000
Other stockholders' equity2,041,000,0001,859,000,0001,912,000,0001,916,000,000
Total stockholders' equity48,667,000,00040,786,000,00039,143,000,00037,037,000,000
Total equity48,719,000,00040,871,000,00039,166,000,00037,058,000,000
Minority interest52,000,00085,000,00023,000,00021,000,000
Total liabilities and total equity114,074,000,000104,035,000,000101,119,000,00096,483,000,000
Total investments5,773,102,0002,720,239,0002,443,128,0001,219,000,000
Total debt29,622,000,00030,114,000,00028,407,000,00029,143,000,000
Net debt23,911,000,00024,626,000,00022,567,000,00022,977,000,000

AstraZeneca PLC Cash Flow Statement

Cash from operations
Cash from investing
Cash flow / share TTM
—
Revenue / share TTM
—
Operating cash flow TTM
—
Period end31/12/202531/12/202431/12/202331/12/2022
Cash from operations14,575,000,00011,861,000,00010,345,000,0009,808,000,000
Cash from investing-6,808,000,000-7,980,000,000-4,064,000,000-2,960,000,000
Cash from financing-7,544,000,000-3,996,000,000-6,567,000,000-6,823,000,000
Net change in cash269,000,000-208,000,000-346,000,000-55,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Net income12,402,000,0008,691,000,0006,899,000,0002,501,000,000
Depreciation and amortization5,733,000,0005,065,000,0004,934,000,0005,480,000,000
Deferred income tax000-619,000,000
Stock-based compensation00579,000,000619,000,000
Change in working capital-1,137,000,000-893,000,000300,000,0003,757,000,000
Accounts receivable0-1,624,000,000-1,425,000,000-1,349,000,000
Inventory0-131,000,000-669,000,0003,941,000,000
Accounts payable001,425,000,0001,349,000,000
Other working capital-1,137,000,000862,000,000969,000,000-184,000,000
Other non-cash items-2,423,000,000-1,002,000,000-2,367,000,000-1,930,000,000
Net cash from operating activities14,575,000,00011,861,000,00010,345,000,0009,808,000,000
Investments in property, plant and equipment-2,810,000,000-1,924,000,000-1,361,000,000-2,571,000,000
Acquisitions (net)-1,240,000,000-3,927,000,000-1,179,000,000-1,061,000,000
Purchases of investments-229,000,000-96,000,000-136,000,000-159,000,000
Sales/maturities of investments131,000,000108,000,000129,000,00042,000,000
Other investing activities-2,660,000,000-2,141,000,000-1,517,000,000789,000,000
Net cash from investing activities-6,808,000,000-7,980,000,000-4,064,000,000-2,960,000,000
Net debt issuance-1,650,000,0001,809,000,000-965,000,000-1,197,000,000
Long-term net debt issuance-2,014,000,0001,840,000,000-1,126,000,000-1,271,000,000
Short-term net debt issuance364,000,000-31,000,000161,000,00074,000,000
Net stock issuance-481,000,000-43,000,00033,000,00029,000,000
Net common stock issuance-481,000,000-43,000,00033,000,00029,000,000
Common stock issuance-481,000,000-43,000,00033,000,00029,000,000
Common stock repurchased0000
Net preferred stock issuance0000
Net dividends paid-4,971,000,000-4,629,000,000-4,481,000,000-4,364,000,000
Common dividends paid-4,971,000,000-4,629,000,000-4,481,000,000-4,364,000,000
Preferred dividends paid0000
Other financing activities-442,000,000-1,133,000,000-1,154,000,000-1,291,000,000
Net cash from financing activities-7,544,000,000-3,996,000,000-6,567,000,000-6,823,000,000
Effect of FX changes on cash46,000,000-93,000,000-60,000,000-80,000,000
Net change in cash269,000,000-208,000,000-346,000,000-55,000,000
Cash at end of period5,698,000,0005,429,000,0005,637,000,0005,983,000,000
Cash at beginning of period5,429,000,0005,637,000,0005,983,000,0006,038,000,000
Operating cash flow14,575,000,00011,861,000,00010,345,000,0009,808,000,000
Capital expenditure-5,905,000,000-4,586,000,000-3,778,000,000-2,571,000,000
Free cash flow8,670,000,0007,275,000,0006,567,000,0007,237,000,000
Income taxes paid0000
Interest paid0000